vs

Side-by-side financial comparison of Eos Energy Enterprises, Inc. (EOSE) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Eos Energy Enterprises, Inc. is the larger business by last-quarter revenue ($58.0M vs $35.5M, roughly 1.6× RECURSION PHARMACEUTICALS, INC.). Eos Energy Enterprises, Inc. runs the higher net margin — -207.7% vs -304.2%, a 96.6% gap on every dollar of revenue. On growth, Eos Energy Enterprises, Inc. posted the faster year-over-year revenue change (699.6% vs 681.7%). RECURSION PHARMACEUTICALS, INC. produced more free cash flow last quarter ($-47.3M vs $-75.2M).

Eos Energy Enterprises, Inc. is an energy storage solutions provider that designs, produces and deploys safe long-duration zinc-based battery systems. It serves utility, commercial, industrial and microgrid customers across North America, Europe and Asia, supporting grid stability and renewable energy integration.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

EOSE vs RXRX — Head-to-Head

Bigger by revenue
EOSE
EOSE
1.6× larger
EOSE
$58.0M
$35.5M
RXRX
Growing faster (revenue YoY)
EOSE
EOSE
+17.9% gap
EOSE
699.6%
681.7%
RXRX
Higher net margin
EOSE
EOSE
96.6% more per $
EOSE
-207.7%
-304.2%
RXRX
More free cash flow
RXRX
RXRX
$27.9M more FCF
RXRX
$-47.3M
$-75.2M
EOSE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EOSE
EOSE
RXRX
RXRX
Revenue
$58.0M
$35.5M
Net Profit
$-120.5M
$-108.1M
Gross Margin
-93.8%
59.8%
Operating Margin
-140.1%
-304.8%
Net Margin
-207.7%
-304.2%
Revenue YoY
699.6%
681.7%
Net Profit YoY
55.1%
39.6%
EPS (diluted)
$-0.53
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EOSE
EOSE
RXRX
RXRX
Q4 25
$58.0M
$35.5M
Q3 25
$30.5M
$5.2M
Q2 25
$15.2M
$19.2M
Q1 25
$10.5M
$14.7M
Q4 24
$7.3M
$4.5M
Q3 24
$26.1M
Q2 24
$14.4M
Q1 24
$13.8M
Net Profit
EOSE
EOSE
RXRX
RXRX
Q4 25
$-120.5M
$-108.1M
Q3 25
$-641.4M
$-162.3M
Q2 25
$-222.9M
$-171.9M
Q1 25
$15.1M
$-202.5M
Q4 24
$-268.1M
$-178.9M
Q3 24
$-95.8M
Q2 24
$-97.5M
Q1 24
$-91.4M
Gross Margin
EOSE
EOSE
RXRX
RXRX
Q4 25
-93.8%
59.8%
Q3 25
-111.2%
-183.8%
Q2 25
-203.2%
-4.9%
Q1 25
-234.7%
-48.0%
Q4 24
-324.0%
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
EOSE
EOSE
RXRX
RXRX
Q4 25
-140.1%
-304.8%
Q3 25
-200.6%
-3327.6%
Q2 25
-419.1%
-916.8%
Q1 25
-506.2%
-1297.9%
Q4 24
-712.8%
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
EOSE
EOSE
RXRX
RXRX
Q4 25
-207.7%
-304.2%
Q3 25
-2102.1%
-3135.3%
Q2 25
-1463.2%
-894.2%
Q1 25
144.7%
-1373.3%
Q4 24
-3696.7%
-3935.5%
Q3 24
-367.5%
Q2 24
-676.6%
Q1 24
-662.4%
EPS (diluted)
EOSE
EOSE
RXRX
RXRX
Q4 25
$-0.53
$-0.17
Q3 25
$-4.91
$-0.36
Q2 25
$-1.05
$-0.41
Q1 25
$-0.20
$-0.50
Q4 24
$-2.30
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EOSE
EOSE
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$568.0M
$743.3M
Total DebtLower is stronger
$813.3M
$9.6M
Stockholders' EquityBook value
$-2.2B
$1.1B
Total Assets
$885.2M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EOSE
EOSE
RXRX
RXRX
Q4 25
$568.0M
$743.3M
Q3 25
$58.7M
$659.8M
Q2 25
$120.2M
$525.1M
Q1 25
$82.6M
$500.5M
Q4 24
$74.3M
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
EOSE
EOSE
RXRX
RXRX
Q4 25
$813.3M
$9.6M
Q3 25
$448.5M
$11.9M
Q2 25
$445.3M
$14.2M
Q1 25
$325.5M
$16.4M
Q4 24
$316.9M
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
EOSE
EOSE
RXRX
RXRX
Q4 25
$-2.2B
$1.1B
Q3 25
$-2.3B
$1.0B
Q2 25
$-1.1B
$919.1M
Q1 25
$-942.2M
$933.9M
Q4 24
$-1.1B
$1.0B
Q3 24
$524.6M
Q2 24
$584.4M
Q1 24
$401.2M
Total Assets
EOSE
EOSE
RXRX
RXRX
Q4 25
$885.2M
$1.5B
Q3 25
$328.2M
$1.4B
Q2 25
$361.0M
$1.3B
Q1 25
$263.3M
$1.3B
Q4 24
$260.3M
$1.4B
Q3 24
$726.5M
Q2 24
$775.9M
Q1 24
$557.8M
Debt / Equity
EOSE
EOSE
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EOSE
EOSE
RXRX
RXRX
Operating Cash FlowLast quarter
$-50.3M
$-46.1M
Free Cash FlowOCF − Capex
$-75.2M
$-47.3M
FCF MarginFCF / Revenue
-129.7%
-133.1%
Capex IntensityCapex / Revenue
43.1%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-265.0M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EOSE
EOSE
RXRX
RXRX
Q4 25
$-50.3M
$-46.1M
Q3 25
$-65.9M
$-117.4M
Q2 25
$-66.1M
$-76.4M
Q1 25
$-28.9M
$-132.0M
Q4 24
$-42.7M
$-115.4M
Q3 24
$-59.2M
Q2 24
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
EOSE
EOSE
RXRX
RXRX
Q4 25
$-75.2M
$-47.3M
Q3 25
$-82.7M
$-117.6M
Q2 25
$-73.2M
$-79.6M
Q1 25
$-33.8M
$-133.8M
Q4 24
$-55.8M
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
EOSE
EOSE
RXRX
RXRX
Q4 25
-129.7%
-133.1%
Q3 25
-271.1%
-2272.5%
Q2 25
-480.2%
-413.9%
Q1 25
-323.6%
-907.4%
Q4 24
-769.1%
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
EOSE
EOSE
RXRX
RXRX
Q4 25
43.1%
3.5%
Q3 25
55.2%
4.7%
Q2 25
46.2%
16.4%
Q1 25
47.0%
12.4%
Q4 24
180.6%
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
EOSE
EOSE
RXRX
RXRX
Q4 25
Q3 25
Q2 25
Q1 25
-1.91×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons